1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Technology appraisal guidance [TA478] Published: 04 October 2017

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 238 KB 04 October 2017  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document PDF 484 KB 24 August 2017  
  • Committee papers PDF 5.13 MB 24 August 2017  
  • Public committee slides PDF 627 KB 24 August 2017  

Draft guidance: 1

  • Draft guidance: 1  
  • Appraisal consultation document PDF 206 KB 14 June 2017  
  • Committee papers PDF 9.49 MB 14 June 2017  
  • Public committee slides PDF 983 KB 14 June 2017  
  • Public committee slides PDF 729 KB 14 June 2017  

Invitation to participate

  • Final scope PDF 100 KB 02 December 2016  
  • Final matrix PDF 173 KB 02 December 2016  
  • NICE's response to comments on the draft scope and provisional matrix PDF 109 KB 02 December 2016  
  • Equality Impact Assessment (Guidance development) PDF 172 KB 02 December 2016